Products for Research Use Only
RegisterLogin

SACLAC

CAT: 0804-HY-158783-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-158783-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SACLAC, a Ceramide analog, is a potent and covalent acid ceramidase (ASAH1; AC) inhibitor with a Ki of 97.1 nM. SACLAC effectively blocks AC activity and induces a decrease in sphingosine 1-phosphate (S1P) and total ceramide levels. SACLAC reduces the levels of splicing factor SF3B1 and alternative Mcl-1 mRNA splicing, increases pro-apoptotic Mcl-1S levels to induce apoptosis in acute myeloid leukemia (AML) cells. SACLAC reduces the leukemic burden in human AML xenograft mouse models[1][2].
CAS Number
2248703-42-4
UNSPSC
12352211
Target
Apoptosis; Bcl-2 Family; Ceramidase; LPL Receptor
Type
Reference compound
Related Pathways
Apoptosis; GPCR/G Protein; Metabolic Enzyme/Protease
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/saclac.html
Purity
99.70
Solubility
DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(CCl)=O
Molecular Formula
C20H40ClNO3
Molecular Weight
377.99
References & Citations
[1]Yadira F Ordóñez, et al. Activity-Based Imaging of Acid Ceramidase in Living Cells. J Am Chem Soc. 2019 May 15;141 (19) :7736-7742. |[2]Jennifer M Pearson, et al. Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia. Mol Cancer Res. 2020 Mar;18 (3) :352-363.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
GTR19229917-01SACLAC

Popular Products